Home/Tag: Invivoscribe

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

2020-05-19T16:22:45+00:00May 19th, 2020|Categories: Press Releases|Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

2020-05-12T17:03:17+00:00May 12th, 2020|Categories: Press Releases|Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

Invivoscribe also Receives National Reimbursement for CDx Assay in Japan

2020-05-29T00:00:58+00:00November 29th, 2018|Categories: Press Releases|Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |

⟵  PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]